Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Company’s Phase III FDA Sickle Cell Treatment Trials

November 22, 2012

Following a meeting on November 5, 2012 with the U.S. Food & Drug Administration (FDA), Dr. Yutaka Niihara offered the following remarks:

“The FDA’s review group unanimously recommended that we proceed to complete our Phase III trial without any modification to the protocol. The trial is directed to study L-glutamine as a treatment for sickle cell disease."